Nicola Goekbuget

Sort by:

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Max S. Topp, Nicola Goekbuget, +22 authors Hagop M Kantarjian
The Lancet. Oncology
2015

BACKGROUND Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19,… (More)

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate…

Max S. Topp, Peter Kufer, +26 authors Ralf C Bargou
Journal of clinical oncology : official journal…
2011

PURPOSE Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In acute… (More)

Treatment of adult acute lymphoblastic leukemia.

Nicola Goekbuget, Dieter Hoelzer
Seminars in hematology
1990

Treatment results in adult acute lymphoblastic leukemia (ALL) have improved considerably in the past decade, with an increase of complete remission rates to 85% to 90% and overall survival rates to… (More)

Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.

Dieter F Hoelzer, Nicola Goekbuget, +6 authors Jan A. Walewski
Blood
2002

We treated 45 adult patients with T-lymphoblastic lymphoma (T-LBL) (age range 15-61 years) with 2 protocols designed for adult acute lymphoblastic leukemia (ALL). An encouraging cure rate of 90% was… (More)

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Hagop M Kantarjian, Daniel J. Deangelo, +11 authors Anjali S. Advani
The New England journal of medicine
2016

BACKGROUND The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin,… (More)

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

Monika Brüggemann, Thorsten Raff, +12 authors Michael Kneba
Blood
2006

Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard-risk (SR) group due to the absence of adverse prognostic factors relapse in 40% to 55% of the cases. To… (More)

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.

Rob Pieters, Stephen P Hunger, +6 authors Ching-Hon Pui
Cancer
2011

Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the… (More)

Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia.

Thomas Burmeister, Stefan Schwartz, +11 authors Eckhard Thiel
Haematologica
2007

RT-PCR detects chimeric BCR-ABL mRNA in approximately 25% of adult acute lymphoblastic leukemia (ALL) cases. Minor breakpoint transcripts (e1a2) are found in about 70% of positive cases and major… (More)

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Barbara Wassmann, Heike Pfeifer, +19 authors Oliver G Ottmann
Blood
2006

The best strategy for incorporating imatinib in front-line treatment of Ph+ acute lymphoblastic leukemia (ALL) has not been established. We enrolled 92 patients with newly diagnosed Ph+ ALL in a… (More)

Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.

Martin Neumann, Sandra Heesch, +16 authors Claudia Dorothea Baldus
Blood
2013

Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a high-risk subgroup of T-lineage ALL characterized by specific stem cell and myeloid features. In adult ETP-ALL, no comprehensive… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences